Mr. Small has served as Neurotech’s Chief Executive Officer since December, 2017. He was previously Neurotech’s Chief Operating Officer from March 2016 to December 2017 and the Company’s Chief Financial Officer from July 2007 to March, 2016. He has in excess of 30 years of both private and public life sciences experience and more than 40 years of overall financial and operational management. He also currently serves as a Trustee, Executive Committee Member and Chairman of the Finance and Business Affairs Committee for the New England College of Optometry. Previously Mr. Small served as Senior Vice President and Chief Financial Officer of Point Therapeutics, a publicly traded biotechnology company focused in developing treatments for various cancers. At Point he was a founding member of the Company and involved in taking the company public and successfully completed several private and public equity offerings. Prior to Point he served as Vice President, Chief Financial Officer at Immulogic Pharmaceutical, Inc., a publicly traded biotechnology company developing treatments for immunological-based disorders. At Immulogic he was involved in completing multiple licensing deals and several public equity offerings. His early career was spent in senior management financial and treasury positions at Dennison Manufacturing Company and he began his career at the public accounting firm of Coopers and Lybrand, LLC. Mr. Small is a CPA and has a BS in Business Administration from Northeastern University in Boston, Massachusetts.